Therapy News and Research

RSS

Migraine therapy alleviates more than just the headache

Treating the pain associated with migraine can also improve the social and psychologic problems experienced by individuals affected by the condition, findings from a systematic review suggest.

10 Oct 2012

Ranibizumab improves driving prospects for AMD patients

Treatment with ranibizumab can preserve and even improve the perceived driving ability of patients with age-related macular degeneration, show the results of two randomized trials.

10 Oct 2012

Non-surgical orthopedic medical devices: an interview with Brian Moore, Director of Sales and Product Marketing from DJO global

Non-surgical orthopedic medical devices are products designed to help relieve pain in specific parts of the body.

10 Oct 2012

UCSF project to explore mystery behind advanced prostate cancer

Many men survive prostate cancer, but thousands of others -- whose cancer spreads -- inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.

10 Oct 2012

Nearly all groups of patients with spinal stenosis do better with surgery

Nearly all groups of patients with spinal stenosis—but not smokers—do better with surgery than with nonsurgical treatment, reports a study in the October 1 issue of Spine.

10 Oct 2012

PARP-1 plays a major role in controlling AR function in prostate cancer patients

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.

10 Oct 2012

ASTRO names distinguished neurosurgeon as 2012 Honorary Member

The American Society for Radiation Oncology (ASTRO) has named Mark P. Carol, MD, a distinguished leader in the fields of intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), as its 2012 Honorary Member, which is the highest honor the Society bestows upon distinguished cancer researchers and leaders in disciplines other than radiation oncology, radiation physics or radiobiology.

10 Oct 2012

Chemotherapy plus immunotherapy can enhance anti-tumor effects in patients with advanced cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Tianjin Medical University Cancer Institute and Hospital in China have discovered that combining chemotherapy drugs and immunotherapy cancer vaccines results in an enhanced anti-tumor effect.

10 Oct 2012

Recovering Treg cells in pancreatic lymph nodes may restore insulin production in type I diabetics

The key to restoring production of insulin in type I diabetic patients, previously known as juvenile diabetes, may be in recovering the population of protective cells known T regulatory cells in the lymph nodes at the "gates" of the pancreas, a new preclinical study published online October 8 in Cellular & Molecular Immunology by researchers in the Department of Bioscience Technologies at Thomas Jefferson University suggests.

10 Oct 2012

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS).

10 Oct 2012

Neuroprotectant success in aneurysm coiling

Treatment with the novel neuroprotective agent NA-1 reduces the number of ischemic infarcts sustained by patients undergoing coiling of cerebral aneurysms, show the ENACT results.

9 Oct 2012

HVLA manipulation comes out top for low-back pain

Spinal high-velocity-low-amplitude manipulation for the treatment of nonspecific low-back pain has shown to be superior to a nonsteroidal anti-inflammatory drug, researchers report.

9 Oct 2012

Innovative treatments can lead to functional improvements in patients with SCIs

A series of rehabilitation studies published in the September 2012 issue of the Archives of Physical Medicine & Rehabilitation demonstrate that innovative treatments for individuals with spinal cord injuries can lead to significant functional improvements in patients and a higher quality of life.

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Study examines trends in HIV mortality

Overall death rates due to human immunodeficiency virus (HIV) infection declined over time between 1993 and 2007 for most men and women by race/ethnicity and educational levels, with the largest absolute decreases for nonwhites, but rates remain high among blacks, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

9 Oct 2012

New blood test can read genetic changes in prostate cancer

Scientists have designed a blood test that reads genetic changes like a barcode - and can pick out aggressive prostate cancers by their particular pattern of gene activity.

9 Oct 2012

HPV status predicts oropharyngeal cancer irradiation response

Human papillomavirus-positive head and neck cancer is more sensitive to the initial effects of radiation therapy than HPV-negative head and neck cancer, suggest study findings.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012